Plan to Enhance Diversity

Albert Einstein College Of Medicine, Bronx NY

Investigators

Linked publications, trials & patents

Abstract

Program Director/Principal Investigator (Last, First, Middle): Chu, Edward PLAN TO ENHANCE DIVERSITY - PROJECT SUMMARY/ABSTRACT The Montefiore Einstein Cancer Center’s overarching mission is to become a national model for reducing cancer incidence and disparities in the most diverse and impoverished catchment area of all NCI-designated cancer centers in the U.S. Our Plan to Enhance Diversity will ensure that all groups that are underrepresented in the cancer workforce, including individuals from very different demographic, racial, ethnic, religious, gender and sexual orientation backgrounds, etc., currently not represented in visible numbers in cancer research, education and clinical care delivery given the population of our catchment area in the Bronx, have the opportunity and are supported to participate and be included in all aspects of our Cancer Center activities. We plan to achieve this goal by establishing, sustaining, and continuously monitoring our investments in institutional infrastructure and implementing programs to establish, promote, and sustain a culture of diversity, equity and inclusivity, increase participation of women, racial/ethnic minorities, and other underrepresented groups in the cancer workforce and in leadership through pipeline program with key stakeholders in the Bronx, and building, by strengthening and evaluating the capacity of the workforce to integrate a culture of diversity, equity and inclusivity excellence in research, clinical care delivery and community engagement. It is essential that an effective plan to enhance diversity must be cross-cutting, and for this reason, we will synergistically coordinate all activities among other components of the Cancer Center such as Community Outreach and Engagement (COE) and Cancer Research, Training and Education Coordination (CRTEC) components, Cancer Epidemiology, Prevention and Control Program, and the clinical services and clinical trials in support of our core mission and vision. OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page